TrialThe Lancet. Infectious diseases2025

Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9-14 years compared with three doses of quadrivalent HPV vaccine in women aged 18-25 years in Costa Rica (PRIMAVERA): a non-randomised, open-label, immunobridging, non-inferiority trial.

Bernal Cortés et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.